Sep 04, 2015 at 16:37 | Source: CNBC-TV18
Ajay Bagga, Market Expert is of the view that one may prefer IT and pharma stocks.
Sep 03, 2015 at 21:59 | Source: Moneycontrol.com
Homegrown drug major Cipla is in advance stage talks to acquire Hetero Drugs' US business, which is run under the Camber Pharmaceuticals brand.
Sep 03, 2015 at 15:26 | Source: CNBC-TV18
Going forward from a 12-18 month perspective Nischal Maheshwari, Head of Institutional Equities at Edelweiss Securities expects a 12-15 percent upside for the market.
Sep 03, 2015 at 10:32 | Source: CNBC-TV18
Sudarshan Sukhani of s2analytics.com is of the view that metal stocks are short selling ideas and prefers private sector banks, pharmaceuticals, IT, Reliance Industries and oil marketing companies.
Sep 03, 2015 at 09:57 | Source: CNBC-TV18
In an interview with CNBC-TV18, Manoj Murlidharan of Religare Securities says market will enter range bound zone soon and has put Ninfty target at 7900.
Sep 02, 2015 at 16:13 | Source: CNBC-TV18
Sudip Bandopadhyay, President at Destimoney Securities is of the view that one can pick Sun Pharma at the current level.
Sep 02, 2015 at 15:22 | Source: CNBC-TV18
Mayuresh Joshi of Angel Broking is of the view that one may prefer Dishman Pharma and Sun Pharma from the pharma space.
Sep 02, 2015 at 15:17 | Source: CNBC-TV18
According to Mayuresh Joshi of Angel Broking, one may buy Aurobindo Pharma on declines for a target of Rs 872.
Sep 02, 2015 at 12:06 | Source: Moneycontrol.com
According to the brokerage, India & core US businesses and generic Gleevec launch are critical to drive its FY17 EBITDA (earnings before interest, tax, depreciation and amortisation). It expects 40 percent Y-o-Y FY17 EBITDA growth for Sun Pharma.
Sep 02, 2015 at 09:51 | Source: CNBC-TV18
Dimensions Consulting CEO Srivastava expects margin expansion in the IT and pharma sector because of weak rupee, but says the overall earnings story for FY16 will be lacklustre